Related Experiment Video

Updated: Aug 18, 2026

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

Genetic and environmental factors affecting the response to statin therapy in patients with molecularly defined

George Miltiadous1, Stavroulla Xenophontos, Eleni Bairaktari

  • 1Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece.

Pharmacogenetics and Genomics
|May 3, 2005
PubMed

Insights

Familial hypercholesterolaemia (FH) is an inherited condition causing high LDL cholesterol. The class of LDL receptor (LDLR) gene mutation significantly impacts statin therapy effectiveness in FH patients.

Area of Science:

  • Genetics and Molecular Biology
  • Cardiovascular Medicine
  • Pharmacogenomics

Background:

  • Familial hypercholesterolaemia (FH) is a prevalent inherited metabolic disorder.
  • Characterized by elevated low-density lipoprotein cholesterol (LDL-C) and early-onset ischemic heart disease.
  • Early diagnosis and intervention are crucial for preventing premature atherosclerosis in FH patients.

Purpose of the Study:

  • To evaluate the impact of genetic factors, specifically LDL receptor (LDLR) gene mutation class, and environmental factors on statin response in FH.
  • To assess the lipid-lowering efficacy of atorvastatin in patients with molecularly defined heterozygous FH.

Main Methods:

  • A cohort of 49 patients with heterozygous FH received atorvastatin 20 mg/day for 12 weeks.
  • Lipid profiles (LDL-C, apoB) were measured pre- and post-treatment.
  • Patients were stratified based on LDLR mutation class (Class V vs. Class II).

Main Results:

  • Atorvastatin therapy reduced LDL-C by 37% and apoB by 36%.
  • Patients with LDLR Class V mutations showed a significantly greater percentage decrease in LDL-C (49%) and apoB (42%) compared to Class II (34% and 35%, respectively).
  • LDLR mutation class was the only significant predictor of statin response in multivariate analysis.

Conclusions:

  • The class of the LDLR gene mutation is a key determinant of the lipid-lowering response to statin therapy in heterozygous FH.
  • Patients with Class V LDLR mutations exhibit a superior response to atorvastatin compared to those with Class II mutations.
  • This finding highlights the importance of genetic profiling for personalized statin treatment strategies in FH.

More Related Videos

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes10:56

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

Published on: September 15, 2018

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...